ST. LOUIS, May 12, 2015 /PRNewswire/ -- Sigma-Aldrich
Corporation's (NASDAQ: SIAL) custom manufacturing business unit,
SAFC® Commercial (www.sigma-aldrich.com/safc), announced
today the strategic expansion of its existing facility in Carlsbad,
Calif. The investment will further enable SAFC to offer clinical
and commercial bulk drug production, as well as fill/finish of
viral products for its gene therapy, viral vaccine and
immunotherapy customers.
"Gene therapy is an emerging technology, and our SAFC and
BioReliance® sites in Carlsbad, Rockville, and Glasgow have supported this growing industry
for years," said Gilles Cottier,
President of SAFC. "This investment is pivotal to our customers and
reflects SAFC's continued dedication to providing the
infrastructure customers need to bring their drugs to market."
The expanded Carlsbad facility
complements a global footprint of GMP services in the virus and
gene therapy segment, including cell banking in Rockville, Md., and manufacturing in the
Glasgow location in Scotland, U.K. The investment was driven by
continued interest in targeted gene therapies for indications such
as hemophilia and cancer immunotherapies (CAR-T cells).
Utilizing the biosafety testing expertise of BioReliance, the
Carlsbad facility provides a full
range of GMP manufacturing and testing services to its customers.
To learn more about the capabilities at the Carlsbad location, please visit:
www.sigmaaldrich.com/safc/carlsbad.
The foregoing release contains forward-looking statements
that can be identified by terminology such as "is expected," "will
enable," "is pivotal" or similar expressions, or by expressed or
implied discussions regarding potential future revenues from
products or services derived therefrom. You should not place undue
reliance on these statements. There can be no guarantee that the
services in SAFC's service offering will continue to meet the
demands of the marketplace. Nor can there be any guarantee that any
of these services will achieve any particular levels of revenue in
the future. Such forward-looking statements reflect the current
views of management regarding future events, and involve known and
unknown risks, uncertainties and other factors that may cause
actual results to be materially different from any future results,
performance or achievements expressed or implied by such
statements. In particular, management's expectations regarding
these services could be affected by, among other things, unexpected
regulatory actions or delays or government regulation generally;
the company's ability to obtain or maintain patent or other
proprietary intellectual property protection; competition in
general; government, industry and general public pricing pressures;
the impact that the foregoing factors could have on the values
attributed to the company's assets and liabilities as recorded in
its consolidated balance sheet, and other risks and factors
referred to in Sigma-Aldrich's current Form 10-K on file with the
U.S. Securities and Exchange Commission. Should one or more of
these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially
from those anticipated, believed, estimated or expected.
Sigma-Aldrich is providing the
information in this press release as of this date and does not
undertake any obligation to update any forward-looking statements
contained in this press release as a result of new information,
future events or otherwise.
About SAFC: SAFC Commercial,
the custom manufacturing and services business unit of
Sigma-Aldrich Corporation, is recognized as a top 10 global
specialty chemicals and biologics supplier. As a trusted
manufacturer for the life science and high-technology industries,
SAFC works closely with customers to resolve development challenges
and accelerate the product pipeline using its global "Centers of
Excellence" and dedicated manufacturing facilities. Its rich
portfolio includes high-purity inorganic materials for
high-technology applications, critical raw materials and extensive
biologics safety testing services for biopharmaceutical
manufacturing, and complex, high-potent APIs and key intermediates
for pharmaceutical manufacturing. For more information, visit
www.sigma-aldrich.com/safc.
About Sigma-Aldrich: Sigma-Aldrich, a
leading Life Science and Technology company focused on enhancing
human health and safety, manufactures and distributes 250,000
chemicals, biochemicals and other essential products to more than
1.4 million customers globally in research and applied labs as well
as in industrial and commercial markets. With three distinct
business units - Research, Applied and SAFC Commercial
- Sigma-Aldrich is committed to enabling science to
improve the quality of life. The Company operates in 37 countries,
has approximately 9,300 employees worldwide and had sales
of $2.79 billion in 2014. For more information about
Sigma-Aldrich, please visit its website
at www.sigma-aldrich.com.
©2015 Sigma-Aldrich Co. LLC. All rights reserved.
Sigma-Aldrich, SAFC and
BioReliance are trademarks of Sigma-Aldrich Co. LLC or its
affiliates, registered in the U.S. and other countries.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/safc-expands-carlsbad-calif-facility-to-support-commercial-scale-gene-therapy-production-testing-and-filling-300081162.html
SOURCE Sigma-Aldrich Corporation